Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib plus pembrolizumab versus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma
MOH_2024-06-02_013454Phase 2Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing zanzalintinib + pembrolizumab with matching placebo + pembrolizumab (2 arms). Started May 2024; status: active, not recruiting.
02
Drugs
zanzalintinibpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2024-06-02_013454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-02_013454.